ZA961161B - Medicinal combination for transfecting and expressing exogenous genes in vivo - Google Patents

Medicinal combination for transfecting and expressing exogenous genes in vivo

Info

Publication number
ZA961161B
ZA961161B ZA961161A ZA961161A ZA961161B ZA 961161 B ZA961161 B ZA 961161B ZA 961161 A ZA961161 A ZA 961161A ZA 961161 A ZA961161 A ZA 961161A ZA 961161 B ZA961161 B ZA 961161B
Authority
ZA
South Africa
Prior art keywords
vivo
transfecting
exogenous genes
expressing exogenous
medicinal combination
Prior art date
Application number
ZA961161A
Other languages
English (en)
Inventor
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Jean-Francois Bach
Original Assignee
Inst Nat Sante Rech Med
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Rhone Poulenc Rorer Sa filed Critical Inst Nat Sante Rech Med
Publication of ZA961161B publication Critical patent/ZA961161B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
ZA961161A 1995-02-14 1996-02-13 Medicinal combination for transfecting and expressing exogenous genes in vivo ZA961161B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
ZA961161B true ZA961161B (en) 1996-08-07

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961161A ZA961161B (en) 1995-02-14 1996-02-13 Medicinal combination for transfecting and expressing exogenous genes in vivo

Country Status (23)

Country Link
US (2) US20030004091A1 (xx)
EP (1) EP0809516B1 (xx)
JP (1) JPH11500430A (xx)
KR (1) KR100402540B1 (xx)
AT (1) ATE204481T1 (xx)
AU (1) AU717218B2 (xx)
BR (1) BR9607310A (xx)
CA (1) CA2211039C (xx)
CZ (1) CZ258197A3 (xx)
DE (1) DE69614668T2 (xx)
DK (1) DK0809516T3 (xx)
ES (1) ES2163612T3 (xx)
FI (1) FI119176B (xx)
FR (1) FR2730411B1 (xx)
GR (1) GR3036438T3 (xx)
HU (1) HU222991B1 (xx)
IL (1) IL117116A0 (xx)
MX (1) MX9706017A (xx)
NO (1) NO320072B1 (xx)
PT (1) PT809516E (xx)
SK (1) SK282235B6 (xx)
WO (1) WO1996025177A1 (xx)
ZA (1) ZA961161B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
ES2371635T3 (es) * 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
FI973323A (fi) 1997-08-13
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
ATE204481T1 (de) 2001-09-15
NO973724D0 (no) 1997-08-13
HU222991B1 (hu) 2004-01-28
SK282235B6 (sk) 2001-12-03
AU717218B2 (en) 2000-03-23
JPH11500430A (ja) 1999-01-12
DK0809516T3 (da) 2001-12-17
FR2730411B1 (fr) 1997-03-28
BR9607310A (pt) 1997-11-25
SK110897A3 (en) 1998-01-14
FR2730411A1 (fr) 1996-08-14
EP0809516B1 (fr) 2001-08-22
KR19980702199A (ko) 1998-07-15
US20030004091A1 (en) 2003-01-02
NO320072B1 (no) 2005-10-17
FI119176B (fi) 2008-08-29
IL117116A0 (en) 1996-06-18
AU4723896A (en) 1996-09-04
HUP9800635A2 (hu) 1998-07-28
KR100402540B1 (ko) 2004-05-07
NO973724L (no) 1997-08-13
MX9706017A (es) 1997-11-29
PT809516E (pt) 2002-02-28
CA2211039A1 (fr) 1996-08-22
FI973323A0 (fi) 1997-08-13
HUP9800635A3 (en) 2000-12-28
CZ258197A3 (en) 1997-11-12
DE69614668T2 (de) 2002-06-27
US20040265276A1 (en) 2004-12-30
DE69614668D1 (de) 2001-09-27
EP0809516A1 (fr) 1997-12-03
WO1996025177A1 (fr) 1996-08-22
GR3036438T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
ZA961161B (en) Medicinal combination for transfecting and expressing exogenous genes in vivo
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
WO1996027663A3 (en) An antisense transcript associated to tumor cells having a t(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
WO1999058656A3 (en) Sustained dna delivery from structural matrices
EP1007717B8 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
HUP9904201A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
IL192893A0 (en) Cell-based gene therapy for the pulmonary system
Agrawal Antisense oligonucleotides as gene expression modulators
AU2298195A (en) An (in vivo) gene expression system